Syncytin is involved in breast cancer-endothelial cell fusions |
| |
Authors: | B. Bjerregaard S. Holck I. J. Christensen L. -I. Larsson |
| |
Affiliation: | (1) Anatomy and Cell Biology, IBHV, KVL, Gronnegaardsvej 7, 1870 Frederiksberg C, Copenhagen, Denmark;(2) Department Pathology, Hvidovre University Hospital, Copenhagen, Denmark;(3) Department of Surgery, Hvidore University Hospital, Copenhagen, Denmark |
| |
Abstract: | Cancer cells can fuse spontaneously with normal host cells, including endothelial cells, and such fusions may strongly modulate the biological behaviour of tumors. However, the underlying mechanisms are unknown. We now show that human breast cancer cell lines and 63 out of 165 (38%) breast cancer specimens express syncytin, an endogenous retroviral envelope protein, previously implicated in fusions between placental trophoblast cells. Additionally, endothelial and cancer cells are shown to express ASCT-2, a receptor for syncytin. Syncytin antisense treatment decreases syncytin expression and inhibits fusions between breast cancer cells and endothelial cells. Moreover, a syncytin inhibitory peptide also inhibits fusions between cancer and endothelial cells. These results are the first to show that syncytin is expressed by human cancer cells and is involved in cancer-endothelial cell fusions. Received 2 May 2006; received after revision 7 June 2006; accepted 12 June 2006 |
| |
Keywords: | Syncytin breast cancer endothelial cell fusion ASCT-2 |
本文献已被 PubMed SpringerLink 等数据库收录! |
|